Next Article in Journal / Special Issue
Models of Hepatocellular Carcinoma and Biomarker Strategy
Previous Article in Journal
The Problems of Radiofrequency Ablation as an Approach for Advanced Unresectable Ductal Pancreatic Carcinoma
Previous Article in Special Issue
Alterations of MicroRNAs in Solid Cancers and Their Prognostic Value
Cancers 2010, 2(3), 1432-1440; doi:10.3390/cancers2031432

PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis

1 Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands 2 First Urology Department, Medical University of Łódź, Poland
* Author to whom correspondence should be addressed.
Received: 17 May 2010 / Revised: 24 June 2010 / Accepted: 5 July 2010 / Published: 6 July 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
View Full-Text   |   Download PDF [182 KB, uploaded 6 July 2010]


The search for the biomarkers to precisely and non-invasively characterize the biology of prostate cancer (PCa) is the focus of many laboratories across the world. Although prostate-specific antigen (PSA) remains the standard diagnostic tool for PCa, its low specificity leads to unnecessary biopsies in a substantial number of patients. More importantly, with the current status of knowledge, it is very difficult to early identify individuals with a life-threatening disease who require an immediate treatment. The significant advances in genetics and biotechnology in recent years has led to the discovery of new molecular markers including PCA3 and the TMPRSS2:ERG genomic fusion. Both PCA3 and TMPRSS2:ERG, compared to PSA, show an increased specificity in PCa detection. However, the quest for a single PCa marker that can fully satisfy urologists and their patients is still ongoing. The aim of this review is to present the recent findings on PCA3 and TMPRSS2:ERG and to describe their clinical implications and performance.
Keywords: prostate cancer; diagnosis; molecular; marker; PCA3; TMPRSS2:ERG prostate cancer; diagnosis; molecular; marker; PCA3; TMPRSS2:ERG
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Salagierski, M.; Schalken, J.A. PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis. Cancers 2010, 2, 1432-1440.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert